Enregistrement - Lobbyistes salariés d'organisations

Objets

• Commerce intérieur
• Commerce international
• Impôts et finances
• Industrie
• Petites entreprises
• Propriété intellectuelle
• Questions touchant les consommateurs
• Relations internationales
• Santé
• Sciences et technologies

Détails sur l'objet

Politique ou Programme

• Health Canada regarding the development of a national pharmacare strategy.
• Health Canada with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders. Related guidance documents include the Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080), the Guidance on Drug Establishment Licences and Drug Establishment Licensing Fees (GUI-0002) and the Guidance on Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104).
• Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
• Participation in Competition Bureau consultations with respect to pharmaceuticals.
• Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
• Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions.
• Provide input into the Patented Medicine Prices Review Board (PMPRB) consultations regarding its Policies, Guidelines and Procedures.
• Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
• Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
• To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat substandard and falsified medicines in Canada and around the world.

Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement

• Health Canada with respect to user fees for therapeutic product regulatory programs.
• Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.

Politique ou Programme, Règlement

• Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
• Participate in Government of Canada consultations with respect to the Regulatory Cooperation Council.

Proposition législative, Projet de loi ou résolution

• Provide input into policy discussions with respect to the potential implementation of a national pharmacare program.
• Provide input into the Government of Canada's negotiations regarding trade negotiations with respect to pharmaceuticals, counterfeit medicines, and intellectual property.
• Provide input into the Government of Canada's negotiations towards a Canada-United States-Mexico Agreement (CUSMA) -- formerly known as the North American Free Trade Agreement (NAFTA) -- and provide input into its implementation.

Techniques de communication

• Communication écrite
• Communication orale
• Appel au grand public

Institutions gouvernementales

• Affaires mondiales Canada (AMC)
• Anciens Combattants Canada (ACC)
• Bureau de la concurrence Canada (BUCO)
• Bureau du Conseil privé (BCP)
• Cabinet du Premier ministre (CPM)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Défense nationale (MDN)
• Emploi et Développement social Canada (EDSC)
• Environnement et Changement climatique Canada (ECCC)
• Finances Canada (FIN)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Patrimoine canadien (PCH)
• Santé Canada (SC)
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Sécurité publique Canada (SP)
• Sénat du Canada
• Transports Canada (TC)
• Tribunal canadien du commerce extérieur (TCCE)

Adresse :
501 - 4100 Yonge Street
Toronto, ON  M2P 2B5
Canada

Numéro de téléphone : 416-223-2333
Numéro de fax : 416-223-2425